LENZ Therapeutics (LENZ) Q3 2026 earnings summary
Event summary combining transcript, slides, and related documents.
Q3 2026 earnings summary
9 Nov, 2026Executive summary
Q3 VIZZ product sales reached $2.6M, up 50% QoQ, with more than 38,000 paid prescriptions and momentum continuing into Q4.
The October reorganization redirects resources toward consumer marketing, access and sales growth, targeting a >50% reduction in 2027 operating expenses.
CEO Eef Schimmelpennink transitions effective Dec. 1, 2026; CFO Dan Chevallard becomes interim CEO while the board searches for a permanent successor.
Financial highlights
Q3 revenue was $3.4M: $2.6M in product sales and $0.8M in license revenue; Q3 2025 revenue was $12.5M, all license revenue.
Nine-month 2026 revenue was $10.8M, including $6.0M in product sales and $4.8M in license revenue, versus $17.5M in nine-month 2025, all license revenue.
Q3 net loss was $31.0M, or $0.99 per share; nine-month net loss was $104.4M, or $3.33 per share.
Cash, cash equivalents and marketable securities totaled $197.3M at Sept. 30, 2026; management expects resources to fund operations for at least 12 months from issuance.
Outlook and guidance
2027 operating expenses target $70M–$75M, excluding stock-based compensation, representing a reduction of >50% from prior estimates.
More than 70% of projected 2027 operating spend is allocated to consumer-driven sales and marketing; the planned organization is ~40 FTEs.
Reorganization activities are expected to be substantially complete in Q4 2026, with estimated net restructuring charges of $5M.
Commercial priorities include broad ECP engagement, consumer demand generation and access through retail, ePharmacy and telehealth.
Latest events from LENZ Therapeutics
- VIZZ pairs sustained near-vision benefits with early prescription traction and global expansion.LENZ
Corporate presentation - Q2 2026 revenue grew to $5.5M on VIZZ sales and licensing, with net loss at $31.9M.LENZ
Q2 2026 - New presbyopia eye drop delivers rapid, lasting vision improvement and targets broad U.S. adoption.LENZ
Morgan Stanley 23rd Annual Global Healthcare Conference - Presbyopia eye drop launch sees strong adoption, positive feedback, and robust market potential.LENZ
TD Cowen 46th Annual Health Care Conference - Q1 2026 revenue hit $1.9M, with strong VIZZ uptake, global expansion, and a $41.5M net loss.LENZ
Q1 2026 - Board recommends electing three directors and ratifying Ernst & Young LLP as auditor for 2026.LENZ
Proxy filing - Virtual meeting to elect three directors and ratify Ernst & Young LLP as auditor.LENZ
Proxy filing - VIZZ launch drove $1.6M in Q4 sales, strong adoption, and major launch investments.LENZ
Q4 2025 - LNZ100 advances toward FDA approval with strong clinical data and $226.2M pro forma cash.LENZ
Q2 2024